(Total Views: 871)
Posted On: 01/30/2022 11:24:53 PM
Post# of 151689
The number of patients Albert Einstein(AE) has enrolled in the covid trials remains unknown. The numbers were low at the start of the month, though that appears in large part due to very low incidence of covid disease in Brazil through December (~3k cases daily for the entirety of Brazil in the latter half of the month). Covid case had since increased dramatically. AE does not appear to have any current competing covid trials (a couple for anticoagulants that seem to be enrolled already). AE is respected academic research organization and an internationally recognized healthcare system.
Though today's new cases and deaths were "only" 134K and 330 respectively, over the last two weeks, the moving averages of cases has nearly tripled from 75K to 200K and more than tripled from 160 to 583.
As a reminder, the critical covid trials is enrolling 316 patients at 23 sites and the moderate/severe trial 612 patients at 27 trial sites.
Both trials will administer up to fours dose of Leronlimab (700 mg IV critical, 700 mg initially, then 350 mg x 3 for moderate) for patient who remain admitted through the 28 day trial period.
Unlike CD12, the critical trials primary endpoint is cumulative proportion of clinical improvement (better and/or faster improvement from a critical state generates a higher score), thus measuring the improvement with leronlimab administration.
The moderate/severe trial essentially measures the avoidance of critical illness in patients initially moderate or severely ill by assessing respiratory failure or death (patients who progress to requiring high flow oxygen, invasive or non-invasive ventilation, ECMO).
As has also been discussed, omicron generates a lower incidence of critical disease, but the mortality rate of those who develop critical illness, appears to be unchanged. The need for leronlimab remains.
Though today's new cases and deaths were "only" 134K and 330 respectively, over the last two weeks, the moving averages of cases has nearly tripled from 75K to 200K and more than tripled from 160 to 583.
As a reminder, the critical covid trials is enrolling 316 patients at 23 sites and the moderate/severe trial 612 patients at 27 trial sites.
Both trials will administer up to fours dose of Leronlimab (700 mg IV critical, 700 mg initially, then 350 mg x 3 for moderate) for patient who remain admitted through the 28 day trial period.
Unlike CD12, the critical trials primary endpoint is cumulative proportion of clinical improvement (better and/or faster improvement from a critical state generates a higher score), thus measuring the improvement with leronlimab administration.
The moderate/severe trial essentially measures the avoidance of critical illness in patients initially moderate or severely ill by assessing respiratory failure or death (patients who progress to requiring high flow oxygen, invasive or non-invasive ventilation, ECMO).
As has also been discussed, omicron generates a lower incidence of critical disease, but the mortality rate of those who develop critical illness, appears to be unchanged. The need for leronlimab remains.
(17)
(0)Scroll down for more posts ▼
